Sign In
Buy BYSI
$1.15
+0.0200 (+1.77%)
At Close: Jul 31, 2026
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
08:00am, Friday, 11'th Jun 2021
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today a
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer t
BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021
04:05pm, Wednesday, 26'th May 2021
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today an
- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
12:10pm, Thursday, 13'th May 2021
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021
08:18am, Monday, 10'th May 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today an
BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q4 2020 Results - Earnings Call Transcript
04:39pm, Saturday, 01'st May 2021
BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q4 2020 Results - Earnings Call Transcript
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
04:37pm, Wednesday, 28'th Apr 2021
- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemothera
BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021
11:22am, Tuesday, 27'th Apr 2021
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative can
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alon
Sizing Up A Bet In BeyondSpring
01:00pm, Thursday, 25'th Mar 2021
Today, we take an in-depth look at BeyondSpring, a small cap concern focused on the development of immuno-oncology cancer therapies. In recent months, the company has addressed its current funding nee
BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
04:01pm, Thursday, 11'th Mar 2021
Webinar on Thursday, March 18 th @ 10:00 a.m. ET
UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
09:19am, Tuesday, 29'th Dec 2020
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
08:00am, Tuesday, 29'th Dec 2020
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
08:00am, Thursday, 17'th Dec 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th
